BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK targeting chimeric degradation activation compound active against wild type and mutant BTK; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187 and BG-C0902, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC. It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company was formerly known as BeiGene, Ltd. and changed its name to BeOne Medicines AG in May 2025. BeOne Medicines AG was founded in 2010 and is based in Basel, Switzerland.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.81B | $2.46B | $1.42B | $1.18B | $308.87M | $428.21M | $198.22M | $238.39M |
| Cost of Revenue | $594.09M | $379.92M | $286.48M | $164.91M | $70.66M | $71.19M | $707.71M | $273.99M |
| Gross Profit | $3.22B | $2.08B | $1.13B | $1.01B | $238.22M | $357.02M | $-509.49M | $-35.60M |
| Gross Margin | 84.41% | 84.55% | 79.77% | 85.98% | 77.12% | 83.38% | -257.03% | -14.94% |
| Operating Expenses | $3.78B | $3.29B | $2.92B | $2.45B | $1.90B | $1.32B | $196.28M | $62.85M |
| Operating Income | $-568.20M | $-1.21B | $-1.79B | $-1.44B | $-1.66B | $-959.89M | $-705.77M | $-98.46M |
| Operating Margin | -14.91% | -49.12% | -126.40% | -122.31% | -536.69% | -224.16% | -356.05% | -41.30% |
| Net Income | $-644.79M | $-881.71M | $-2.00B | $-1.46B | $-1.62B | $-948.63M | $-673.77M | $-93.11M |
| Net Margin | -16.92% | -35.86% | -141.52% | -123.93% | -526.10% | -221.53% | -339.91% | -39.06% |
| EPS (Basic) | $-6.12 | $-8.45 | $-19.37 | $-15.21 | $-19.11 | $-15.86 | $-12.09 | $-2.21 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |